Efficacy and safety of CAR-T cell therapy in minorities

Astha Thakkar; Michelly Abreu; Kith Pradhan; R. Alejandro Sica; Aditi Shastri; Noah Kornblum; Nishi Shah; Ioannis Mantzaris; Kira Gritsman; Eric Feldman; Richard Elkind; Susan Green-Lorenzen; Amit Verma; Ira Braunschweig; Mendel Goldfinger

doi:10.1038/s41409-022-01670-1

Efficacy and safety of CAR-T cell therapy in minorities

Astha Thakkar, Michelly Abreu, Kith Pradhan, R. Alejandro Sica, Aditi Shastri, Noah Kornblum, Nishi Shah, Ioannis Mantzaris, Kira Gritsman, Eric Feldman, Richard Elkind, Susan Green-Lorenzen, Amit Verma, Ira Braunschweig, Mendel Goldfinger

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	1187-1190
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	57
Issue number	7
DOIs	https://doi.org/10.1038/s41409-022-01670-1
State	Published - Jul 2022

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/s41409-022-01670-1

Cite this

@article{59d95f5fd9a54ee29c65141c2592c68e,

title = "Efficacy and safety of CAR-T cell therapy in minorities",

author = "Astha Thakkar and Michelly Abreu and Kith Pradhan and Sica, {R. Alejandro} and Aditi Shastri and Noah Kornblum and Nishi Shah and Ioannis Mantzaris and Kira Gritsman and Eric Feldman and Richard Elkind and Susan Green-Lorenzen and Amit Verma and Ira Braunschweig and Mendel Goldfinger",

note = "Funding Information: We would like to acknowledge all the physician assistants and nurses on the bone marrow transplant and cellular therapy unit for their compassionate care for these patients. These studies were supported by grants from Izzy Englander, Jane and Myles Dempsey Family, Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program and the Leukemia and Lymphoma Society. Funding Information: AV has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly and is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene and received honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. KG has received research funding from ionctura, SA and ADC therapeutics. AS has received honorarium from GLG, Guidepoint, Onclive, consultation fee from Janssen Pharmaceuticals, advisory board fee from Rigel Pharmaceuticals, research funding from Kymera Therapeutics. AT, MA, KP, RAS, NK, NS, IM, EF, SGL, RE, IB and MG have nothing to disclose. ",

year = "2022",

month = jul,

doi = "10.1038/s41409-022-01670-1",

language = "English (US)",

volume = "57",

pages = "1187--1190",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "7",

}

TY - JOUR

T1 - Efficacy and safety of CAR-T cell therapy in minorities

AU - Thakkar, Astha

AU - Abreu, Michelly

AU - Pradhan, Kith

AU - Sica, R. Alejandro

AU - Shastri, Aditi

AU - Kornblum, Noah

AU - Shah, Nishi

AU - Mantzaris, Ioannis

AU - Gritsman, Kira

AU - Feldman, Eric

AU - Elkind, Richard

AU - Green-Lorenzen, Susan

AU - Verma, Amit

AU - Braunschweig, Ira

AU - Goldfinger, Mendel

N1 - Funding Information: We would like to acknowledge all the physician assistants and nurses on the bone marrow transplant and cellular therapy unit for their compassionate care for these patients. These studies were supported by grants from Izzy Englander, Jane and Myles Dempsey Family, Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program and the Leukemia and Lymphoma Society. Funding Information: AV has received research funding from Prelude, BMS, GSK, Incyte, Medpacto, Curis and Eli Lilly and is a scientific advisor for Stelexis, Novartis, Acceleron and Celgene and received honoraria from Stelexis and Janssen and holds equity in Stelexis and Throws Exception. KG has received research funding from ionctura, SA and ADC therapeutics. AS has received honorarium from GLG, Guidepoint, Onclive, consultation fee from Janssen Pharmaceuticals, advisory board fee from Rigel Pharmaceuticals, research funding from Kymera Therapeutics. AT, MA, KP, RAS, NK, NS, IM, EF, SGL, RE, IB and MG have nothing to disclose.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85128944520&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85128944520&partnerID=8YFLogxK

U2 - 10.1038/s41409-022-01670-1

DO - 10.1038/s41409-022-01670-1

M3 - Letter

C2 - 35484206

AN - SCOPUS:85128944520

SN - 0268-3369

VL - 57

SP - 1187

EP - 1190

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 7

ER -

Efficacy and safety of CAR-T cell therapy in minorities

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this